BioMarin Pharmaceutical Inc. (BMRN)

BioMarin Pharmaceutical Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	268.74	348.9	426.86	167.65	141.56	-64.08
Depreciation & Amortization	73.9	79.56	96.43	104.39	101.97	108.04
Stock-Based Compensation	187.17	181.41	201.57	207.1	196.31	197.26
Other Adjustments	165.29	511.79	64.38	16.67	-167.55	-2.72
Change in Receivables	-177.62	-228.05	-57.91	-190.44	-82.03	65.57
Changes in Inventories	-48.1	-116.93	-63.53	-157.06	-68.26	-35.06
Changes in Accounts Payable	71.89	66.14	-32.24	68.85	59.02	15.69
Changes in Other Operating Activities	-10.29	-14.81	-62.72	-57.9	-5.1	19.83
Operating Cash Flow	874.25	827.99	572.84	159.26	175.9	304.54
Operating Cash Flow Growth	24.85%	44.54%	259.69%	-9.46%	-42.24%	256.75%
Capital Expenditures	-107.19	-103.04	-85.42	-96.69	-120.96	-95.58
Sale of Property, Plant & Equipment	-	-	10	-	103.33	-
Purchases of Intangible Assets	-7.8	-7.94	-11.99	-10.92	-10.58	-23.65
Purchases of Investments	-292.39	-355.88	-410.25	-868.5	-611.81	-937.14
Proceeds from Sale of Investments	1,027	337.8	633.02	864.86	620	691.05
Payments for Business Acquisitions	-	-285.19	-	-	-	-
Other Investing Activities	6.11	1.14	-	-	-	-0.99
Investing Cash Flow	339.52	-414.24	136.49	-111.24	-20.03	-366.31
Long-Term Debt Issued	850	-	-	-	-	-
Long-Term Debt Repaid	-	-	-494.99	-	-	-
Net Long-Term Debt Issued (Repaid)	850	-	-494.99	-	-	-
Issuance of Common Stock	10.61	14.46	49.28	69.35	69.33	49.19
Repurchase of Common Stock	-45.37	-55.97	-77.56	-76.32	-54.28	-45.81
Net Common Stock Issued (Repurchased)	-34.76	-41.51	-28.28	-6.97	15.05	3.39
Other Financing Activities	-9.54	-0.89	-3.18	-11.76	-33.7	-3.44
Financing Cash Flow	809.55	-42.39	-526.45	-18.73	-18.65	-0.05
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.31	-2.52	4.83	1.31	0.03	-0.06
Net Cash Flow	2,024	368.84	187.72	30.6	137.26	-61.88
Free Cash Flow	767.06	724.96	487.42	62.57	54.94	208.96
Free Cash Flow Growth	5.81%	48.73%	679.02%	13.88%	-73.71%	-
FCF Margin	23.66%	22.51%	17.08%	2.59%	2.62%	11.32%
Free Cash Flow Per Share	3.94	3.67	2.48	0.33	0.29	1.14
Levered Free Cash Flow	1,099	259.81	-215.61	29.24	108.22	-51.16
Unlevered Free Cash Flow	199.9	207.02	234.03	26.76	119.01	-57.1

Updated May 5, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q